0000912282-23-000133.txt : 20230615 0000912282-23-000133.hdr.sgml : 20230615 20230615135253 ACCESSION NUMBER: 0000912282-23-000133 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230614 FILED AS OF DATE: 20230615 DATE AS OF CHANGE: 20230615 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Disbrow Joshua R. CENTRAL INDEX KEY: 0001566240 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38247 FILM NUMBER: 231016900 MAIL ADDRESS: STREET 1: AMPIO PHARMACEUTICALS, INC. STREET 2: 5445 DTC PARKWAY, SUITE 925 CITY: GREENWOOD VILLAGE STATE: CO ZIP: 80111 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AYTU BIOPHARMA, INC CENTRAL INDEX KEY: 0001385818 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 470883144 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 373 INVERNESS PARKWAY STREET 2: SUITE 206 CITY: ENGLEWOOD STATE: CO ZIP: 80112 BUSINESS PHONE: (720) 437-6580 MAIL ADDRESS: STREET 1: 373 INVERNESS PARKWAY STREET 2: SUITE 206 CITY: ENGLEWOOD STATE: CO ZIP: 80112 FORMER COMPANY: FORMER CONFORMED NAME: AYTU BIOSCIENCE, INC DATE OF NAME CHANGE: 20150609 FORMER COMPANY: FORMER CONFORMED NAME: AYTU BIOSCIENCE, INC. DATE OF NAME CHANGE: 20150609 FORMER COMPANY: FORMER CONFORMED NAME: Rosewind CORP DATE OF NAME CHANGE: 20070110 4 1 form4.xml X0407 4 2023-06-14 0001385818 AYTU BIOPHARMA, INC AYTU 0001566240 Disbrow Joshua R. C/O AYTU BIOPHARMA, INC. 373 INVERNESS PARKWAY, SUITE 206 ENGLEWOOD CO 80112 true true Chief Executive Officer false Common Shares 2023-06-14 4 P 0 14000 1.8628 A 71591 D The purchase price reported in Column 4 above is an average weighted price. These shares were purchased in multiple transactions at prices ranging from $1.79 to $1.87, inclusive. The reporting person undertakes to provide to AYTU Biopharma, Inc., any security holder of AYTU Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Reflects a 1:20 reverse stock split effected by the Issuer on January 4, 2023. /s/ Mark Oki as attorney-in-fact for Joshua R. Disbrow 2023-06-15